NPWR experienced a dramatic 74% decline in total assets from $2.3B to $599.7M, accompanied by substantial increases in R&D spending and new technology licensing dependencies.
The massive asset reduction suggests either a major divestiture, write-down, or restructuring that fundamentally alters the company's scale and financial profile. The shift toward dependency on third-party PCC technology licensing from Entropy introduces new execution risks and reduces control over core technology development, while substantially higher R&D expenses indicate intensified development efforts despite the reduced asset base.
NPWR's financial position underwent a dramatic transformation with total assets declining by nearly three-quarters to $599.7M, while liabilities were cut roughly in half to $64.5M. R&D expenses grew substantially to $99.5M reflecting increased development activity, even as capital expenditures were meaningfully reduced to $33.2M. The overall picture suggests a company that has undergone major restructuring or asset divestiture while simultaneously ramping up research spending and shifting toward a more asset-light, technology-focused model.
Total assets contracted 73.9% — asset sales, write-downs, or balance sheet optimization underway.
R&D investment increased 55.8% — signals commitment to future product development, though near-term margin impact.
Capex reduced 51.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities reduced 51.1% — deleveraging improves balance sheet strength and financial flexibility.
Cash declined 39.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 33% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →